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ABSTRACT: The complementary coiled coil forming pep-
tides E4 [(EIAALEK)4] and K4 [(KIAALKE)4] are known to
trigger liposomal membrane fusion when tethered to lipid
vesicles in the form of lipopeptides. In this study, we examined
whether these coiled coil forming peptides can be used for
drug delivery applications. First, we prepared E4 peptide
modiﬁed liposomes containing the far-red ﬂuorescent dye TO-
PRO-3 iodide (E4-Lipo-TP3) and conﬁrmed that E4-liposomes
could deliver TP3 into HeLa cells expressing K4 peptide on
the membrane (HeLa-K) under cell culture conditions in a
selective manner. Next, we prepared doxorubicin-containing
E4-liposomes (E4-Lipo-DOX) and conﬁrmed that E4-lip-
osomes could also deliver DOX into HeLa-K cells. Moreover,
E4-Lipo-DOX showed enhanced cytotoxicity toward HeLa-K cells compared to free doxorubicin. To prove the suitability of
E4/K4 coiled coil formation for in vivo drug delivery, we injected E4-Lipo-TP3 or E4-Lipo-DOX into zebraﬁsh xenografts of
HeLa-K. As a result, E4-liposomes delivered TP3 to the implanted HeLa-K cells, and E4-Lipo-DOX could suppress cancer
proliferation in the xenograft when compared to nontargeted conditions (i.e., zebraﬁsh xenograft with free DOX injection).
These data demonstrate that coiled coil formation enables drug selectivity and eﬃcacy in vivo. It is envisaged that these
ﬁndings are a step forward toward biorthogonal targeting systems as a tool for clinical drug delivery.
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The design of anticancer drug delivery systems is of greatinterest, as many of the drugs in the clinic cause serioustoxic side eﬀects due to nonspeciﬁc cytotoxicity,
outweighing the therapeutic eﬀect. Therefore, targeted drug
delivery systems are being developed, for example, micellar-,
liposomal-, and nanoparticle-based drug formulations com-
bined with peptide or surface-antibody targeting, photo-
chemical internalization, and ultrasound stimulation.1 Of
these, liposomes are the most clinically established nanosystems
for drug delivery, e.g., doxorubicin (DOX)-containing lip-
osomes.2,3 However, these clinically approved drugs are
nontargeted and rely on the enhanced permeability and
retention eﬀect, resulting in cardiotoxicity, thereby limiting
their cumulative dose in cancer patients. To overcome this
problem, liposomes have been conjugated with active targeting
ligands, such as antibodies and cell-penetrating peptides, for
target-speciﬁc drug delivery.4−6 However, as these targeted
ligands frequently interact with natural membrane receptors,
liposome internalization occurs via endocytosis. As a result,
drug accumulation in early endosomes induces lysosomal
activation, leading to rapid degradation of these drugs inside
cells.7 Furthermore, the number of these “cell-speciﬁc”
receptors is limited, thereby putting restrictions on this type
of drug delivery system.
Therefore, it is important for the development of new drug
delivery systems to avoid lysosomal degradation in order to
enhance the delivery eﬃciency. We decided to design an
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artiﬁcial biorthogonal targeting system that would be able to
target liposomes and other nanoparticles more eﬃciently to the
tissue of interest. In addition, this targeting system should also
be able to enhance cellular uptake, preferentially in a
nonendocytic manner. For this, synthetic coiled coils are
attractive candidates as a new targeting motif.8,9 Coiled coil
motifs are found in approximately 10% of all protein sequences
in nature,10 and many of these noncovalent peptide motifs play
a vital role in the eﬃcient transport of molecules across
membranes. For example, in the process of HIV infection, viral
entry into CD4-positive cells is accomplished by intramolecular
coiled coil formation between helices of viral glycoprotein
gp41.11 In neuronal exocytosis, docking of transport vesicles to
the target plasma membrane is mediated by the coiled coil
formation of complementary SNARE protein subunits on the
opposing membranes.12 This forces the opposing membranes
into close proximity, resulting ultimately in lipid mixing
followed by pore formation and concomitant content transfer.
These natural systems have inspired researchers to design drug
delivery systems based on noncovalent binding of two
macromolecules. To introduce bioactive compounds into the
cytosol of the target cells, various non-natural coiled coils have
been used to decorate nanoparticles,13,14 which in turn are
complexed to DNA antisense oligonucleotides,15 short
interfering RNAs,16 proteins,17 drugs,18,19 or vaccines.20
Recently coiled coil motifs have also been used in drug-free
therapeutic systems.21,22
In our previous study, we developed a fully synthetic
membrane fusion system composed of a complementary pair23
of lipidated coiled coil peptides, denoted K and E,18 which are
covalently linked to cholesterol anchors via a poly(ethylene
glycol) linker, yielding lipopeptides CPK and CPE.24 We
demonstrated that this complementary lipopeptide pair was
able to induce eﬃcient fusion between liposomes.25,26 The E/K
coiled coil formation is thought to be responsible for speciﬁc
molecular recognition,27,28 and recently membrane fusion
between liposomes and cells without triggering endocytosis
was achieved (Yang et al., unpublished data). This system
seems suitable for drug delivery, as the drug inside these
liposomes avoids lysosomal degradation. While coiled coil
formation induced membrane fusion has shown to be successful
to deliver drugs in vitro, it has to be conﬁrmed whether these
synthetic peptide pairs are also functional in an in vivo
environment. In this study we therefore used a human cancer
cell xenograft in a zebraﬁsh embryo to investigate whether
coiled coil formation can be used to speciﬁcally deliver drugs to
tumor cells in vivo.
RESULTS AND DISCUSSION
E4-Liposomes Deliver TP3 to HeLa Cells That
Genetically Express K4 Peptide in Vitro. Our objective is
to use a pair of complementary coiled coil forming peptides, E
and K,29 of which one is conjugated to a liposome to introduce
chemicals into peptide-conjugated cancer cells in zebraﬁsh
(Scheme 1). The coiled coil peptide E, (EIAALEK)4, was
conjugated to a PEG4 spacer (PEG = poly(ethylene glycol))
and cholesterol linker, yielding lipopeptide CPE4, then inserted
into the bilayer of liposomes containing the ﬂuorescent dye
TO-PRO-3 iodide (TP3) (denoted E4-Lipo-TP3; Scheme 1A).
TP3 is a DNA-intercalating ﬂuorescent dye and cell membrane
impermeable and stains DNA only when it is actively taken up
by live cells.30 We previously conﬁrmed that E4-Lipo-TP3 could
deliver TP3 into the cytosol of HeLa cells that were pretreated
with cholesterol-PEG4-K4 (CPK4).
28 While targeted drug
delivery under in vitro conditions was thus successfully
achieved, demonstrating the in vivo functionality of these
synthetic peptides would be a signiﬁcant step forward. Due to
the fast turnover of membrane components in dividing cells,
CPK4 inserted in a cell membrane is not expected to remain
throughout the zebraﬁsh xenotransplantation setup and experi-
ments. For this reason, we created HeLa cells constitutively
expressing a genetically encoded K4 peptide on their cell
membrane (denoted HeLa-K), by fusing it to the trans-
membrane domain of the human platelet-derived growth factor
receptor (PDGFR-TMD).31 The fusion protein is preceded by
a mouse IgK-leader sequence for eﬃcient secretion and
localization on the cell membrane of the K4-fusion protein.
Functional display of the K4 peptide on the outside of the cell
membrane was veriﬁed in a binding experiment using a
carboxyﬂuorescein-labeled E4 peptide (ﬂuorescent E4; Figure
S1A). Analogously to HeLa-K cells, we also created HeLa-E
cells that potentially expressed E4 peptide on their cell
membrane and HeLa-ctrl cells that only expressed the
transmembrane domain of PDGFR. Fluorescently labeled
CPK4-liposomes (K4-Lipo-NBD) were bound to the cell
membrane of HeLa-E cells (Figure S2); however ﬂuorescent
E4 peptide was taken up by the cells (Figure S1C). Ono et al.
already demonstrated that the positive charge of the K4 peptide
allowed nonspeciﬁc binding to negatively charged cell
membranes.32 Thus, we decided to continue with HeLa-K
cells and E4 peptide in the following study.
Scheme 1. Drug Delivery by E4/K4 Coiled Coil Formation in Cells (A) and Zebraﬁsh (B)
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To investigate whether E4-liposomes could deliver TP3 to
HeLa-K cells, HeLa-K cells were exposed to E4-Lipo-TP3 for 15
min. This resulted in the appearance of a bright TP3 signal in
the cells (Figure 1A). Control experiments in which non-
modiﬁed TP3-liposomes (Lipo-TP3; Figure 1C) or free TP3
(Figure 1D) was added to the HeLa-K cells showed less
ﬂuorescent signal in the cells. In addition, when E4-Lipo-TP3
was added to control HeLa cells (HeLa-ctrl), which express
only PDGFR-TMD, also no TP3 signal was observed (Figure
1B). These results indicate that the coiled coil formation
between E4 on the liposome and K4 on the cell membrane leads
to delivery of liposomal contents into the cell in a selective
manner.
E4-Liposomes Can Deliver TP3 in a Zebraﬁsh
Xenograft of HeLa-K Cells. Zebraﬁsh is becoming a suitable
model for characterization of nanoparticles against cancer,
because of phenotypic and molecular conservation of cancer
development in zebraﬁsh and humans.33 In addition, the
transparency of zebraﬁsh embryos enables visualizing ﬂuo-
rescently labeled cancer cells and nanoparticles through their
body wall. To monitor the fate of the implanted cells in
zebraﬁsh, HeLa-K and HeLa-ctrl cells were labeled with a red
ﬂuorescent protein that was expressed from a transfected
retroviral vector expressing tdTomato (tdTom). We injected
the resulting HeLa-K-tdTom or HeLa-ctrl-tdTom cells into the
blood circulation of zebraﬁsh larvae at 48 h postfertilization
(hpf), according to a previous study.34 We used transgenic
zebraﬁsh that express vascular-speciﬁc EGFP to visualize their
vasculatures. Five hours post cell injection (hpi), we conﬁrmed
that the injected cells accumulated in the caudal hematopoietic
Figure 1. E4/K4 coiled coil formation mediated TP3 delivery into the cytosol. HeLa-K or control HeLa (HeLa-ctrl) cells were treated with 0.25
mM E4-Lipo-TP3, Lipo-TP3 (without E4 peptide), or 2.5 μM free TP3 for 15 min. After three washes with culture medium, the cells were
imaged. E4-Lipo-TP3 can deliver the TP3 into HeLa-K cells (A), not into HeLa-ctrl cells (B). (C) Without E4 peptide, liposomes could not
deliver the TP3 into HeLa-K cells. (D) TP3 without liposome also could not deliver TP3. Green: TP3. The scale bar represents 25 μm.
ACS Nano Article
DOI: 10.1021/acsnano.6b01410
ACS Nano 2016, 10, 7428−7435
7430
(CHT) region. Then, E4-Lipo-TP3 or Lipo-TP3 was injected
into the circulation from the posterior cardinal vein (CV).
Immediately after E4-Lipo-TP3 injection, no TP3 signal could
be detected in the xenografts. However, at 24 hpi, TP3
accumulation was observed in HeLa-K-tdTom cells in the CHT
region (Figure 2A). Control experiments in which one of the
two peptides was omitted (HeLa-K with Lipo-TP3 (Figure 2B)
and free TP3 [Figure S2A], and HeLa-ctrl with E4-Lipo-TP3
[Figure S2B]) showed no TP3 uptake by the HeLa cells. These
results demonstrated that E4/K4 coiled coil formation regulates
delivery of liposomal cargo to the targeted cells in an in vivo
setting.
E4/K4 Coiled Coil Formation Enhances DOX Cytotox-
icity. Having demonstrated the feasibility of the E4/K4 system
to target xenografted cancer cells in zebraﬁsh, we next
investigated whether our E4-liposomes could also deliver an
anticancer drug such as doxorubicin (E4-Lipo-DOX). DOX has
been commonly used as a routine anticancer drug in combined
chemotherapy against a variety of tumors.35 DOX interacts with
DNA by intercalation and disruption of topoisomerase-II-
mediated DNA repair, ultimately leading to cell death.36
Noteworthy, DOX is a popular research tool due to its inherent
ﬂuorescence associated with the central anthracycline chromo-
phore group. This allows visualization of DOX distribution in
various tissues or cells via ﬂuorescence imaging.37 Indeed, we
were able to visualize DOX intake into HeLa-K cells. After 15
min incubation with 0.25 mM E4-Lipo-DOX (1 mM DOX-
containing E4-liposome, equal to 0.25 mM free-DOX
concentration), DOX ﬂuorescent signal was already observed
in the cytosol (Figure 3A). Five hours after washout of E4-Lipo-
DOX from the culture medium, DOX signal had increased
(Figure 3B). Mohan et al. reported that the DOX ﬂuorescence
Figure 2. E4/K4 coiled coil formation delivers the content in the liposome to cancer cells in the xenograft zebraﬁsh. HeLa-K cells (50−100
cells) were injected into the duct of Cuvier of 48 hpf zebraﬁsh. Five hours after implantation (hpi), 1 nL of 1 mM E4-Lipo-TP3 or Lipo-TP3
was injected into the CV and imaged at 72 hpf. (A) E4-Lipo-TP3 can deliver the TP3 to HeLa-K in the xenograft zebraﬁsh, while (B) Lipo-
TP3 could not. White, red, and green indicate vasculatures, cancer cells, and TP3, respectively. The scale bar represents 200 μm.
Figure 3. E4/K4 coiled coil formation promotes doxorubicin intake
and cytotoxicity. HeLa-K cells were incubated with 0.25 mM E4-
Lipo-DOX for 15 min, and after three washes with culture medium,
the cells were imaged (A). After 5 h, the cells were imaged again
using the same settings (B). Red indicates DOX. The scale bar
represents 25 μm. For images of negative controls, see
supplementary Figure S3. (C) Cell viability after DOX delivery.
HeLa-K cells were incubated with diﬀerent concentrations of E4-
Lipo-DOX (red circles), Lipo-DOX (black triangles), or free-DOX
(open circles) for 12 h, then washed three times. Twenty-four
hours after treatment, cell viability was measured. n = 4, error bar
indicates SD. *P < 0.05.
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inside cells increases in a time-dependent manner because of
the alternation of DOX’s binding partners: DNA, histones, and
phospholipids.37 Thus, we assumed that DOX-phospholipid
and DOX-DNA-histone complexes would be detected at this
time point. In contrast, control experiments in which E4 peptide
was omitted from the liposomes (HeLa-K with Lipo-DOX
[Figure S3A] or using free DOX [Figure S3B]) showed very
low cellular uptake of DOX. As expected, free DOX was not
taken up by HeLa-ctrl (Figure S3C) and HeLa-E cells (Figure
S3D), similarly to HeLa-K. We repeated the experiment in the
presence of several well-known endocytosis inhibitors in order
to study the pathway of cellular uptake (Figure S6). It was
shown that uptake via endocytosis was the minor pathway,
suggesting that fusion might be the major pathway. However,
additional studies are required to conﬁrm this ﬁnding.
To investigate whether coiled coil mediated delivery
enhances the cytotoxicity of DOX, we treated HeLa-K cells
with E4-Lipo-DOX, Lipo-DOX, or free DOX for 12 h. As a
result, 1 μM E4-Lipo-DOX exhibited around 80% reduction in
the number of HeLa-K cells, while free DOX had no
measurable eﬀect at the same concentration (Figure 3C). In
addition, Lipo-DOX showed the same toxicity as that of free
DOX to HeLa-K cells. This result indicates that E4/K4 coiled
coil formation increases the cytotoxicity of DOX and reduces
the dose required for the induction of cancer cell death.
Interestingly, under nontargeting conditions with free DOX,
HeLa-ctrl cells (Figure S4, open circles) seem more sensitive
than HeLa-K cells (Figure 3C, open circles). Membranous
expression of K4 peptide might have some protective eﬀects to
the cells; however the IC50 values of DOX for HeLa-ctrl and
HeLa-K cells are similar: 4.0 and 5.3 μM, respectively.
E4/K4 Coiled Coil Formation Enhances Anticancer
Eﬃcacy of DOX in Xenografts. To investigate the toxicity of
DOX toward cancer cells in vivo, we conducted another
zebraﬁsh xenograft experiment similar to the TP3 study above.
We injected HeLa-K-tdTom cells into the circulation from the
duct of Cuvier at 48 hpf, followed by E4-Lipo-DOX, Lipo-DOX,
or free DOX injection at 5 hpi. Twenty-four hours after DOX
injection, these xenografts were imaged using ﬂuorescent
microscopy (Figure 4A). As illustrated by the images in Figure
4A, the ﬂuorescence of the Hela-K-tdTom cells was
substantially more reduced by treatment with E4-Lipo-DOX
(second image) than by treatment with either Lipo-DOX (third
image) or free DOX (fourth image). Quantiﬁcation of the
ﬂuorescent intensities showed that injection of E4-Lipo-DOX
resulted in a signiﬁcantly (P < 0.05) reduced tumor cell
proliferation compared to Lipo-DOX or free DOX treatment
(Figure 4B). Other nontargeting conditions (HeLa-K-tdTom
with Lipo-DOX and free-DOX) did not exhibit signiﬁcant
reduction of cancer cell burden, similarly to the in vitro
experiment in Figure 3C. As described in the Materials and
Methods, we injected 1 nL of 1 mM liposomes containing 0.25
mM DOX. Based on a wet weight estimation of 240 μg for
zebraﬁsh larvae,38 the injection volume of DOX was equal to 1
μmol/kgBW (kilogram per body weight). In the clinic, DOX is
usually injected into the circulation of cancer patients at a
concentration of 2.5 mg/kgBW, which equals 5.16 μmol/
kgBW.39 Therefore, the administered amount of DOX using E4-
liposomes was 5-fold lower than that used in a clinical setting
with lesser opportunity for exhibition of cardiac toxicity, while
the anticancer eﬃcacy of E4-Lipo-DOX is far greater than that
of free-DOX.
Figure 4. E4/K4 coiled coil formation enhances anticancer property of doxorubicin in the xenografts. (A) HeLa-K or HeLa-ctrl cells were
injected into the duct of Cuvier of 48 hpf zebraﬁsh. After 5 h, 1 nL of 1 mM E4-Lipo-DOX, Lipo-DOX, or 0.25 mM free-DOX was injected
from the CV and imaged at 72 hpf. HeLa-K xenograft with E4-Lipo-DOX injection (left upper panel) shows the decrease of the injected cells.
Green and red indicate vasculatures and cancer cells, respectively. (B) Quantiﬁcation of the cancer proliferation in the xenografts. Cancer cell
proliferation was calculated as the ratio of tdTomato ﬂuorescence intensity in the tumor area relative to that at 5 hpi. n = 10−12, error bar =
+SE, *P < 0.05.
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CONCLUSION
Targeted drug delivery systems should increase the eﬃcacy of a
drug and concomitantly reduce the toxic side eﬀects caused by
oﬀ-target reactions. Coiled coil motifs were recently used in a
“drug-free therapeutic system” to speciﬁcally kill cancer cells.40
In this study, we demonstrated that coiled coil formation
between liposomes and live cells enables the in vivo delivery of
an anticancer drug encapsulated in CPE-decorated liposomes to
the targeted cells in an animal model. This is one of the ﬁrst
examples using a synthetic coiled coil motif for in vivo targeted
drug delivery. Although this system currently requires K4
peptide expression on the cell membrane of targeted cells in
zebraﬁsh xenografts, this method can be used for animal testing
of a wide range of drug candidates because of the surprising
degree of functional conservation in basic cell-biological
processes between zebraﬁsh and mammals.41 Furthermore,
the combination of coiled coil mediated delivery and zebraﬁsh
xenografts of human cancer has the potential to become a
powerful and rapid in vivo drug-screening platform. For future
clinical applications, however, it will be necessary to introduce
K4 peptide to the targeted cells or tissues of interest (e.g.,
tumor). This might be achieved by injection of a PEGylated
CPK that can be locally deshielded by irradation with light,27
conjugation of K4 peptide to cancer-speciﬁc cell membrane
antibodies (e.g., Her2 antibody42) or direct introduction of our
K4-PDGFR-TMD construct using adeno-associated virus vector
injection.43 The proposed improvements of the current method
should enable spatiotemporal control of liposomal drug
targeting in the near future. These approaches to introduce
K4 peptide into diseased tissues or cells combined with the
enhanced drug selectivity circumventing lysosomal degradation
might increase the drug eﬃcacy and reduce toxic side eﬀects.
MATERIALS AND METHODS
Zebraﬁsh Strain, Husbandry, and Egg Collection. Tg (ﬂi1:
EGFP) zebraﬁsh44 were used in this study. Livestock were maintained
and handled according to the guidelines from http://zﬁn.org.
Fertilization was performed by natural spawning at the beginning of
the light period, and eggs were raised at 28 °C. All experimental
procedures were conducted in compliance with the directives of the
animal welfare committee of Leiden University.
Plasmids. The insert designs for membrane expression of K4 and
E4 peptide are described in Supplementary Methods. The insert
sequences were synthesized by BaseClear (Leiden, The Netherlands),
then digested with SalI and NotI and ligated into episomal plasmid
pEBMulti-Hyg (Wako Pure Chemicals, Osaka, Japan) to create
pEBM-K and pEBM-E. The backbone vector harbors OriP (replication
origin) and EBNA-1 derived from Epstein−Barr virus, which allows
the distribution of this plasmid to daughter cells by episomal
replication to generate stable transformants.45
Cells. HeLa human cervical cancer cells were obtained from the
American Type Culture Collection (Manassas, VA, USA). The cells
were maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Life Technologies, Carlsbad, CA, USA), supplemented with 10% fetal
bovine serum (FCS; Life Technologies), 100 units/mL of penicillin
(Sigma-Aldrich, St. Louis, MO, USA), and 100 μg/mL streptomycin
(Sigma-Aldrich) at 37 °C with 5% CO2. To construct HeLa-K and
HeLa-E cells, HeLa cells were transfected with pEBM-K and pEBM-E
plasmids, respectively, and cultured in the presence of hygromycin B
(200 μg/mL; Sigma-Aldrich) for at least 2 weeks to obtain stable
transformants. To create control cells (HeLa-ctrl), HeLa cells were
transfected with pEBM harboring PDGFR-TMD (see Supplementary
Methods). For tdTomato ﬂuorescent protein expression, the cells were
infected with tdTomato lentivirus (pLenti-tdTom-Bla; a gift from Dr.
Maciej Olszewski) according to the standard protocol. The tdTomato
cells were cultured in the presence of blasticidin (10 μg/mL; Life
Technologies) to obtain stable transformants.
Cell Imaging. The cells were seeded in an eight-well slide (μ-Slide
8 well; Ibidi, Munich, Germany) at a density of 2.5 × 104 cells per well
in DMEM−10% FCS medium without phenol red and cultured
overnight. Then, the medium was refreshed and test compounds were
added (TP3 or DOX-containing liposomes, which were diluted to a
ﬁnal concentration using DMEM [− phenol red)]. After incubation
for 15 min, cells were washed three times with medium. The
ﬂuorescent images were acquired using a Leica TCS SP8 confocal laser
scanning microscope (Leica Microsystems, Wetzlar, Germany) and
merged with Leica application suite advanced ﬂuorescence software
(Leica Microsystems) or ImageJ software (National Institutes of
Health, Bethesda, MD, USA). The wavelength settings for TP3 and
DOX were Ex/Em: 641/662 nm (Ex laser: 633 nm) and 480/580 nm
(Ex laser: 532 nm), respectively.46
Zebraﬁsh Xenografts and Compound Treatment. HeLa cell
implantation was performed as previously reported.34 In brief,
dechorionized 48 hpf zebraﬁsh were anaesthetized with 0.003%
tricaine (MS222; Sigma-Aldrich). Then trypsinized HeLa cells (100−
200 cells) were injected into the duct of Cuvier by using a Pneumatic
Pico pump and a manipulator (World Precision Instruments, Sarasota,
FL, USA). After implantation, zebraﬁsh were maintained at 34 °C. Five
hours after implantation, 1 nL of test compounds was injected into the
caudal vein using the Pico pump with a ﬁne glass needle. For live
imaging, xenografts were anaesthetized and mounted in 0.6% low-
melting agarose. Fluorescent image acquisition was performed using a
Leica MZ16FA stereo-microscope (Leica Microsystems). Images were
adjusted for brightness and contrast using ImageJ.
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